Pharmacological properties of whale shark (Rhincodon typus) melanocortin-2 receptor and melancortin-5 receptor: Interaction with MRAP1 and MRAP2

被引:2
|
作者
Hoglin, Brianne E. [1 ]
Miner, Marin [1 ]
Dores, Robert M. [1 ]
机构
[1] Univ Denver, Dept Biol Sci, Denver, CO 80210 USA
关键词
Whale Shark; Melanocortin receptors; MRAP1; MRAP2; Cartilaginous Fish; CHICKEN; SYNTENY;
D O I
10.1016/j.ygcen.2021.113915
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the current study, the whale shark (ws; Rhincodon typus) melanocortin-2 receptor (MC2R) co-expressed with wsMRAP1 in Chinese Hamster Ovary (CHO) Cells could be stimulated in a dose dependent manner by ACTH (1-24) with an EC50 of 2.6 x 10(-10) M +/- 9.7 x 10(-11). When the receptor was expressed alone, stimulation was only observed at [10(-6) M]. A comparable increase in sensitivity to stimulation by srDes-Ac-alpha MSH was also observed when the receptor was co-expressed with wsMRAP1. Furthermore, co-expression with wsMRAP1 significantly increased the trafficking of wsMC2R to the plasma membrane of CHO cells. Surprisingly, co-expression with wsMRAP2 also increased sensitivity to stimulation by ACTH(1-24) and srDes-Ac-alpha MSH, and increased trafficking of the receptor to the plasma membrane. These observations are in sharp contrast to the response of MC2R orthologs of bony vertebrates which have an obligate requirement for co-expression with MRAP1 for both trafficking to the plasma membrane and activation, whereas, co-expression with MRAP2 in-creases trafficking, but has minimal effects on activation. In addition, when comparing the activation features of wsMC2R with those of the elephant shark MC2R and red stingray MC2R orthologs, both similarities and differences are observed. The spectrum of features for cartilaginous fish MC2R orthologs will be discussed. A second objective of this study was to determine whether wsMC5R has features in common with wsMC2R in terms of ligand selectivity and interaction with wsMRAP paralogs. While wsMC5R can be activated by either srACTH (1-24) or srDes-Ac-alpha MSH, and co-expression with wsMRAP1 enhances this activation, wsMRAP1 had no effect on the trafficking of wsMC5R. In addition, co-expression with wsMRAP2 had no positive or negative effect on either ligand sensitivity or trafficking of wsMC5R.
引用
下载
收藏
页数:7
相关论文
共 46 条
  • [41] General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy) ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl] methyl]-1H-benzimidazole-7-carboxylate .2. Effect on cardiovascular system and renal functions
    Kito, G
    Ito, K
    Shiomi, M
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1996, 46 (07): : 681 - 686
  • [42] Pharmacological properties and discriminative stimulus effects of a novel and selective 5-HT2 receptor agonist AL-38022A [(S)-2-(8,9-dihydro-7H-pyrano[2,3-g]indazol-1-yl)-1-methylethylamine]
    May, Jesse A.
    Sharif, Najam A.
    Chen, Hwang-Hsing
    Liao, John C.
    Kelly, Curtis R.
    Glennon, Richard A.
    Young, Richard
    Li, Jun-Xu
    Rice, Kenner C.
    France, Charles R.
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2009, 91 (03) : 307 - 314
  • [43] General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]1H-benzimidazole-7-carboxylate .1. Effects on central nervous system and other properties
    Kito, G
    Morimoto, S
    Shiomi, M
    ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 1996, 46 (06): : 572 - 579
  • [44] THE PHARMACOLOGICAL PROPERTIES OF 2-N-(3-[3-(1-PIPERIDINOMETHYL)-PHENOXY]PROPYL)AMINO-5-AMINO-1,3,4-THIADIAZOLE (TAS), A NEW HISTAMINE H2-RECEPTOR ANTAGONIST - COMPARISON WITH RANITIDINE AND CIMETIDINE
    TSURIYA, Y
    MATSUKAWA, H
    AOKI, H
    SEYA, M
    JAPANESE JOURNAL OF PHARMACOLOGY, 1984, 36 : P90 - P90
  • [45] Pharmacological profile and antiparkinsonian properties of the novel nociceptin/orphanin FQ receptor antagonist 1-[1-cyclooctylmethyl-5-(1-hydroxy-1-methyl-ethyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-3-ethyl-1,3-dihydro-benzoimidazol-2-one (GF-4)
    Volta, Mattia
    Marti, Matteo
    McDonald, John
    Molinari, Stefano
    Camarda, Valeria
    Pela, Michela
    Trapella, Claudio
    Morari, Michele
    PEPTIDES, 2010, 31 (06) : 1194 - 1204
  • [46] Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist:: In vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039)
    Rorick-Kehn, Linda M.
    Johnson, Bryan G.
    Burkey, Jennifer L.
    Wright, Rebecca A.
    Calligaro, David O.
    Marek, Gerard J.
    Nisenbaum, Eric S.
    Catlow, John T.
    Kingston, Ann E.
    Giera, Deborah D.
    Herin, Marc F.
    Monn, James A.
    McKinzie, David L.
    Schoepp, Darryle D.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 321 (01): : 308 - 317